Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL44723 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL6506568 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL28208695 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL5086108 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL6506370 | 1.00 | HRH3 (0.70) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL23682856 | 0.97 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL11486347 | 0.97 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| Bromide SCHEMBL10551492 | 0.97 | HRH3 (0.67) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL22151380 | 0.97 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H | |
| SCHEMBL27096 | 0.97 | HRH3 (0.75) | HRH3GNAI3GNAO1GNAI1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103073878-B | Polyamide composition, and preparation method and application thereof | TIANJIN KINGFA NEW MATERIAL CO LTD | 2014-12-24 | — | — | CN | claimed |
| CN-104072981-A | Halogen-free flame retardant polyamide material and preparation method thereof | Suzhou chuangjia plastic co ltd | 2014-10-01 | — | — | CN | claimed |
| CN-103073878-A | Polyamide composition, and preparation method and application thereof | TIANJIN JINFA NEW MATERIAL CO LTD | 2013-05-01 | — | — | CN | claimed |
| US-20240400784-A1 | Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition | LG CHEM, LTD. (KR) | 2024-12-05 | — | — | US | disclosed |
| US-20230012756-A1 | TIME BASED TRIGGERING OF DYNAMIC TEMPLATES | KnowBe4, Inc. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | UNIV DREXEL (US) | 2022-12-08 | — | — | US | disclosed |
| WO-2021067604-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | DREXEL UNIVERSITY (US) | 2021-04-08 | — | — | WO | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | DALCOR PHARMA UK LTD., STOCKPORT ZUG BRANCH (CH) | 2020-07-16 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| CN-108027353-A | SOLID PHASE EXTRACTION, DERIVATIZATION WITH CROWN ETHERS, AND MASS SPECTROMETRY, METHODS, REAGENTS AND KITS | 帝肯样品制备股份有限公司 | 2018-05-11 | — | — | CN | disclosed |
| US-20060035155-A1 | Nonaqueous electrolyte solution for secondary battery and nonaqueous electrolyte secondary battery | SANYO ELECTRIC CO., LTD. (JP) | 2006-02-16 | — | — | US | disclosed |
| WO-2005082892-A2 | TRIAZOLE COMPOUNDS AS ANTIBACTERIAL AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-09-09 | — | — | WO | disclosed |
| EP-1535913-A1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2005-06-01 | — | — | EP | disclosed |
| CN-1171928-C | Polyamide resin composition and process for producing the same | ������������ʽ���� | 2004-10-20 | — | — | CN | disclosed |
| CN-1275148-A | Polyamide resin composition and process for producing the same | ASAHI CHEMICAL IND (JP) | 2000-11-29 | — | — | CN | disclosed |
| US-4046909-A | Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-09-06 | — | — | US | disclosed |
| US-4046909-A | Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants | MCNEIL LABORATORIES, INCORPORATED (US) | 1977-09-06 | — | — | US | disclosed |
| US-3998958-A | Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-12-21 | — | — | US | disclosed |
| US-3998958-A | Pyrrolidylidene, piperidylidene and hexahydroazepinylidene ureas as CNS depressants | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | RAD52, RECQL, RAD50 | HRH3 2354/4885GNAI3 1409/4885GNAO1 2483/4885 |
| US-20200222406-A1 | METHODS FOR TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND LOWERING RISK OF CARDIOVASCULAR EVENTS | HMGCR, PCSK9, FABP3 | HRH3 4303/4885GNAI3 1743/4885GNAO1 2521/4885 |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | HRH3 2523/4885GNAI3 222/4885GNAO1 198/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | HRH3 2523/4885GNAI3 222/4885GNAO1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.